PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations.…
| Price | $1.51 |
|---|---|
| Market cap | $80.26M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 1.02-1.88 |
| Beta | 1.37 |
Explore PMVP's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.